Genedu Weekly Report on Bioeconomy Industry Dynamics 20250506 Files Prospectus
Johnson & Johnson
Medical Device R&D and Manufacturer
Click above "BGI Win-Win"Follow Us
Information Catalog
Synthetic Biology
Innovative Medical Devices
Biological Monitoring Technology
Biopharmaceuticals
China Pharmaceuticals 2025Supervision Network Information and StatisticsPlanning Work Conference Held
On April 28, the 2025 National Drug Administration Network Information and Statistics Conference was held in Fuzhou, Fujian. The conference pointed out that in 2024, drug regulatory authorities at all levels in China adhered to leading the modernization of drug supervision with information technology, further accelerated the integrated construction of smart supervision, and strengthened innovative applications in regulation.Belief and StatisticsReach new heights in work. The meeting emphasized that 2025 is the final year of the "14th Five-Year Plan," and it is essential to persist in leading the modernization of pharmaceutical regulation through informatization, ensuring the successful implementation of smart pharmaceutical supervision and statistical tasks.
NMPA Releases "Medical DeviceOnline Sales QualityQuality Management Standards
To standardize the online sales behavior of medical devices and ensure public safety in using medical equipment, the National Medical Products Administration officially released the "Quality Management Standard for Online Sales of Medical Devices" on the 28th. This "Standard" will come into effect on October 1, 2025, setting clear requirements in various aspects such as qualification review, information display, and risk prevention and control. It further reinforces the primary responsibilities of online medical device sales enterprises and e-commerce platforms, promoting high-quality development in the industry.
Medium View News
Johnson & Johnson May Suffer Losses Under Tariff Impact2.9 billion
Recently, Johnson & Johnson issued a tariff impact warning. The company stated that, based on the tariffs on goods and raw materials announced by the Trump administration, Johnson & Johnson is expected to face a profit loss of $400 million (approximately RMB 2.92 billion). The company indicated that its medical technology division would be significantly affected by the tariffs. This forecast is based on the announced tariff plans and implementation timelines, with related costs including tariffs from Mexico and Canada, tariffs on steel and aluminum for certain products (which have a smaller impact), and tariffs imposed by China. Among these, tariff costs associated with the Chinese market may be a stronger influencing factor. In particular, products originating from the U.S. and sold to China will be heavily impacted. Some commentators noted that Johnson & Johnson's tariff challenges could be a sign that equipment manufacturers affected by tariffs in China and other international markets might adjust their guidance this quarter.
Hong Kong Proprietary Chinese Medicine Accelerates Expansion into the Mainland Market
Hong Kong Health Department announced on the 28th that it would assist the industry in submitting application materials under the new requirements, allowing more eligible Hong Kong-registered traditional oral Chinese patent medicines to accelerate their expansion into the mainland market and promote the development of Hong Kong's traditional Chinese medicine industry. Since the simplification of the registration and approval process for Hong Kong and Macao registered traditional external-use Chinese patent medicines in 2021, 13 Hong Kong-registered traditional external-use Chinese patent medicines have been listed in the mainland through the simplified process. Currently, the total number of Hong Kong-registered Chinese patent medicines is approximately 8,200, with about 5,000 oral medicines. Among them, around 200 have been on the market for 15 years or more and possess a Good Manufacturing Practice (GMP) certificate for Chinese patent medicines.
In the first quarter of 2025, the market price of traditional Chinese medicinal materials continues to decline.
Driven by the Dual Forces of Supply-Demand Restructuring and Policy Regulation, Prices of Chinese Herbal Medicines Undergo a Deep Adjustment, Bringing Substantial Cost Improvements to Downstream Traditional Chinese Medicine Enterprises. The Kangmei China Chinese Herbal Medicine Price Index Fell from Around 2253 Points Near Its High in July 2024 to Approximately 1782 Points on April 30 This Year, Marking a Decline of Over 20%, Clearly Reflecting an Overall Downward Trend in the Market Prices of Chinese Herbal Medicines.
Guangzhou Implements "Code-Based Settlement" for Medicines at Primary and Lower-Level Designated Medical Institutions
Information Times reported that, starting from May 1st, all designated primary-level and below medical institutions in the city (including community health service centers, township health centers, etc.) will fully implement the settlement of medical insurance drugs based on drug traceability codes. When insured patients settle their Western medicine or Chinese patent medicine through medical insurance at these institutions, each box of medicine will be precisely linked to its drug traceability code, achieving full-process closed-loop supervision with "traceable sources, trackable destinations, and accountable responsibilities," adding a solid barrier for medication safety.
The National Health Commission and three other departments recently released the "Notice on Launching the 'Pediatric and Mental Health Services Year' Campaign (2025-2027)"
The Notice clearly states that by 2027, common and frequently-occurring diseases in children will be basically resolved within the city and county levels, major diseases will be treated within the region, continuity and convenience of pediatric visits will be further enhanced, and the patient experience will be significantly improved.
Science and Technology News
FDA Plans to Fully Phase Out Petroleum-Based Synthetic Colors, Precision Fermentation Natural Colors Welcome New Opportunities
Recently, the U.S. Department of Health and Human Services and the U.S. Food and Drug Administration (FDA) announced a series of new measures requiring the food industry to gradually phase out the use of petroleum-based synthetic dyes in all products, including sports drinks, yogurt, candy, fruit snacks, and more.
According to the statement, the FDA will take the following actions: establish national standards and timelines for the food industry to transition from petroleum-based dyes to natural alternatives; initiate the process to revoke authorization for two synthetic food colorings – Citrus Red No. 2 and Orange B – within the next few months; collaborate with the industry to eliminate the remaining six synthetic dyes – Green No. 3, Red No. 40, Yellow No. 5, Yellow No. 6, Blue No. 1, and Blue No. 2 – from the food supply by the end of next year; authorize four new natural color additives within the coming weeks while expediting the review and approval of other additives; partner with the National Institutes of Health (NIH) to conduct a comprehensive study on how food additives affect children's health and development; require food companies to phase out Red No. 3 ahead of the previously mandated deadline of 2027-2028.
As the FDA announces a phase-out of petroleum-based dyes, states across the U.S. are actively promoting policies to eliminate artificial colors. Earlier this year, West Virginia became the first state to ban most synthetic food dyes, citing risks to children's neurobehavioral health. More than twenty other states are considering similar legislation.
Moreover, food companies are also facing pressure from consumers. Over the past year, cereal manufacturer WK Kellogg Co. has faced consumer protests at its headquarters, demanding that the company remove artificial colors from products like Froot Loops.
Earlier this year, Robert F. Kennedy Jr., the U.S. Secretary of Health and Human Services, met with food industry giants such as Kraft Heinz, PepsiCo, and General Mills to discuss the removal of synthetic dyes from their supply chains. Groups representing various sectors of the food industry expressed their intention to comply with this policy. The International Dairy Foods Association, representing dairy companies, announced a voluntary commitment to phase out artificial colors in products sold in schools before the start of the 2026-2027 school year.
Recently, creative giant VML, player in the field of genetic engineering The Organoid Company, and sustainable biotechnology company Lab-Grown Leather have joined forces to develop the world's first leather made from the DNA of the extinct T-Rex (T-Rex Leather).
Lab-Grown Leather, a subsidiary of BSF Enterprise PLC (LSE: BSFA) that focuses on tissue-engineered materials, specializes in producing lab-cultivated genuine leather, with its flagship product being "Elemental Leather™." The company utilizes scaffold-free tissue engineering technology, allowing cells (including engineered cells) to self-assemble into natural structures.
Elemental Leather™ is entirely made from animal cells and the proteins they produce, forming the same structure as traditional leather. This makes the material identical to traditional leather in both structure and genetics, with the same durability, feel, and versatility.
Organoid is committed to reducing the complexity of drug development by combining cost-effective organoid disease models with digital biology. Its platform enables the scalable production of stem cell-derived organoids and integrates advanced digital biology tools to accelerate the design-test-build cycle for therapeutic drugs. By combining predictive in vitro systems with computational drug design, Organoid is transforming the drug discovery process, allowing research groups and biotechnology companies of all sizes to rapidly and precisely develop treatments.
In this project, Lab-Grown Leather provides a proprietary tissue engineering platform (ATEP™), while Organoid contributes expertise in protein and genome engineering.
The press release indicates that T-Rex leather will first be used for luxury accessories, with plans to launch a flagship fashion piece by the end of 2025. After the launch, the partners aim to scale up production for use in industries beyond fashion, including automotive and smart textiles.
The company stated that this T. rex-based material is fully biodegradable. Interestingly, VML was also involved in the development of the "mammoth meatball" project, a bold attempt that used lab-grown meat derived from reconstructed mammoth DNA in 2023.
Scientists Propose DNA Nanotag Concept for 3D Model Reconstruction of Targets
The main research direction of Dr. Yang Yuhe's group at the National Center for Nanoscience and Technology is to analyze the mechanism of antigen-antibody interactions through structural biology methods, thereby understanding the response patterns of the immune system, and using this as a guide for novel vaccine design, antiviral drug development, and other related topics.
This work explores the potential of DNA nano-tags in assisting electron microscopy imaging. The related paper discusses three advantages of DNA nanostructures as nano-tags.
First, DNA nanostructures are highly programmable structures that can be precisely designed into any shape at the nanoscale using existing technologies.
Secondly, a large number of papers have already proven that DNA nanostructures can be easily modified with different proteins and other functional molecules.
Third, DNANanostructures have also been shown to possess a certain degree of stability, maintaining their structural integrity at least within the time scale of cryogenic sample preparation.
Robert Langer's Team Develops Biodegradable Microparticles with 83% Vitamin A Recovery Rate, Collaborating with Gates Foundation to Explore Product Implementation
In the study, the research team utilized a polymer previously developed by the Langer Lab — poly(β-amino esters) (PAE), which has shown significant potential in gene delivery and other medical applications. It is biodegradable and can break down into sugars and amino acids.
By adjusting the basic composition of the aforementioned materials, the team was able to precisely regulate properties such as PAE’s hydrophobicity, mechanical strength, and pH sensitivity. In the study, they designed five candidate materials and screened out a polymer with the best performance; this "optimal" polymer is capable of dissolving even in acidic environments like the human stomach.
Subsequently, they demonstrated the application potential of these polymeric microparticles. For instance, they can be used to encapsulate micronutrients such as vitamins A, D, E, C, zinc, and iron. Some nutrients are typically highly sensitive to heat and light, but after being encapsulated by the microparticles, they remain stable even when heated in boiling water for two hours.
Moreover, they found that even after being stored for six months in a high-temperature and high-humidity environment, more than half of the encapsulated nutrients remained undamaged.
At the same time, they also explored the potential of these microparticles to replace microbeads commonly found in cleaning products. They discovered that when the microparticles were mixed with soap foam, they could more effectively remove permanent marker and waterproof eyeliner traces from the skin, with significantly better cleaning results than using soap alone. Compared with traditional cleansers containing polyethylene microbeads, these microparticles demonstrated a superior ability to adsorb potentially toxic elements such as heavy metals.
Tsinghua University Establishes "Artificial Intelligence Hospital"
On the morning of April 26, Tsinghua University held the inauguration ceremony for the Artificial Intelligence Hospital and the 2025 All-Faculty and Staff Conference of the School of Medicine in the Main Building Reception Hall. The construction of Tsinghua AI Agent Hospital will be carried out in stages. In the initial phase, an AI hospital system will be built based on the university’s comprehensive AI deployment and multidisciplinary integration of medical engineering. It will rely on Beijing Tsinghua Changgung Hospital and Beijing Tsinghua Changgung Internet Hospital for trial operations, with pilot programs in general practice, ophthalmology, radiology, and respiratory medicine. In the future, it aims to build an "AI + healthcare + education + research" closed-loop ecosystem to promote the efficient expansion and balanced distribution of high-quality medical resources, committing to make affordable and sustainable high-quality healthcare accessible to more people.
Tu Youyou Elected as Foreign Associate of the US National Academy of Sciences
On April 30, the National Academy of Sciences of the United States announced the list of newly elected academicians, with a total of 120 academicians and 30 foreign associates elected in recognition of their outstanding and sustained achievements in original research. Professor Tu Youyou from the Artemisinin Research Center of the China Academy of Chinese Medical Sciences, winner of the Nobel Prize in Physiology or Medicine, was elected as a foreign associate of the US National Academy of Sciences. Previously, Chinese scientists including Yuan Longping, Zhang Qifa, Li Jiayang, Dennis Lo Yuk-ming, Shi Yigong, Yang Huanming, George F. Gao, Yan Ning, Cao Xiaofeng, Kang Le, and Wang Yifang were elected as foreign associates of the US National Academy of Sciences.
2. Synthetic Biology
Synthetic Biology Applied in Chemical Industry & Medical Cosmetology
This round of financing was led by CDH VGC and Tianze Capital, with participation from Guohong Jiaxin and InnoAngel Fund. As a globally leading enterprise in the research and development of enzyme-electrode coupling technology, Jinhe Bio's founding team comes from Oxford University, possessing profound technical R&D and commercial incubation experience. This financing will boost its new product development, capacity expansion, technology optimization, and daily operations, with the potential to achieve greater breakthroughs in the application field of enzyme-electrode coupling technology.
Meibai Bio Completes Tens of Millions in Financing
Recently, Beijing Meibai Pharmaceutical Biotechnology Development Co., Ltd. ("Meibai Bio" for short) has completed an A++ round of financing worth tens of millions of yuan. This round of financing was led by Cofo Medical (301087.SZ), with medium- and long-term funding support provided by Zhongguancun Technology Leasing (1601.HK), and WinX Capital serving as the exclusive financial advisor. The proceeds from this round of financing will mainly be used to further advance the research and development and industrialization of the company’s series of human cell extracellular matrix (ECM) regenerative materials products. Additionally, it will accelerate the clinical registration and commercial promotion of Class III medical devices based on human ECM regenerative materials. Medical material technology has undergone several iterations, evolving from first-generation bio-inert materials primarily composed of metals, gradually progressing to second-generation biocompatible and controllably degradable biomedical materials. By the late 1990s, researchers began combining the two independent concepts of bioactive materials and degradable materials, initiating the research of third-generation bio-regenerative materials. These materials can stimulate specific responses at the molecular level, regulate molecular signaling pathways or cellular behavior through their physicochemical properties, promote cell adhesion and migration, thereby achieving human tissue regeneration. This represents a significant and increasingly important trend in the biomedical materials industry.
Kangma Biotech Receives Hundreds of Millions in Series C Funding from Bin Zayed Group
Kangma Biotech Completes Over Hundreds of Millions of Dollars in Series C Financing, with Investment from the UAE Bin Zayed Group. The company owns the world's first cell-free protein synthesis bioreactor, and its D2P technology increases protein production efficiency by 100 times. A production line capable of producing 100,000 tons has been established. The funds will be used to expand commercial production capacity for products such as artificial hemoglobin and medical aesthetics anti-aging solutions, further consolidating its 80% market share in the field of synthetic biology.
3. Innovative Medical Devices
Innovative Medical Devices
Recently, Hefei Synaire Medical Technology Co., Ltd. (referred to as Synaire) completed an angel round of financing worth tens of millions of RMB. This round was led by Huagai Capital, with participation from JoyMed Technology and Hefei Binhu Financial Investment. The funds will mainly be used for core product development, clinical validation, registration applications, and global brand strategy.
Synaire, established in February 2024 and located in Hefei, Anhui, launched its first product that integrates "technological performance" with "ultimate aesthetics." Targeting both home and travel scenarios, the product combines AI intelligence, physiological closed-loop control, modular design, and fashionable aesthetics. Synaire focuses on the mid-to-high-end market segment monopolized by brands like ResMed, swiftly entering with a strategy of "high-end performance + mid-range pricing." The company starts with a B2B approach (hospitals, pharmacies, insurance) and gradually penetrates the household consumer market through B2C, establishing a brand evolution path of "professional-first, then consumer-focused." While rooted in China, Synaire simultaneously expands into international markets, aiming to complete CE/FDA registration by early 2026 and build a marketing network covering key European and American markets. The company has assembled an internationally experienced core team, with members from leading enterprises such as Mindray, ResMed, Philips, and Roche, covering critical areas like product globalization, channel management, and DTC marketing.
Angzhuo Medical, established on December 16, 2015, focuses on the research and development of medical ultrasound instruments. Based on the mechanism and effects of the interaction between sound waves and biological tissues, the company provides clinical solutions for medical ultrasound in the fields of medical ultrasound imaging, ultrasound diagnosis and treatment, and rehabilitation assessment. Angzhuo Medical has a professional technical R&D team dedicated to offering high-quality medical ultrasound products and services to medical institutions.
The product achieves an operational precision of 0.1mm through AI algorithms, addressing the shortage of retinal surgery doctors. It is planned to enter the Class III medical device certification phase by 2026.
Shanghai Biomedical Fund Leads the Investment! Another Medical Device Company in Zhangjiang Completes a New Round of Financing
On April 23, the Zhangtong News team learned that Shanghai Changde Medical Technology Co., Ltd. (hereinafter referred to as: Changde Medical) completed an A+ round of financing exceeding 100 million yuan.This round of financing was led by the Shanghai Biomedical Fund under Shanghai Industrial Capital, with Xingzheng Capital as a follower. Existing shareholders Junlian Capital and Huajie Gaojing continued to increase their investment.
Changde Medical was founded in 2021 and is located in Zhangjiang, Shanghai. The company is committed to providing complete solutions for peripheral vascular diseases. Currently, Changde Medical has built a product matrix covering interventional treatment for lower limb arterial stenosis, thrombus management, venous disease intervention, and chronic disease management. In 2024, Changde Medical was awarded the titles of "National High-tech Enterprise," "Specialized, Refined, Unique, and Innovative Small and Medium-sized Enterprise," and "Technology-based Small and Medium-sized Enterprise."
The founder and core team of Changde Medical have rich experience in the research and development, clinical registration, and commercialization of interventional consumables, and have a deep understanding of the focused industry.
Ms. Miaozheng Hua, founder, chairwoman, and general manager of Changde Medical, has over 20 years of experience in the vascular intervention field. She previously served as the president of Shanghai MicroPort CardioFlow Medtech Corporation (Stock Code: 688016.SH, Abbreviation: CardioFlow Medtech), a listed company in the cardiovascular intervention sector, and successfully led CardioFlow Medtech to be listed on the STAR Market in July 2019, making it one of the first 25 companies to debut on the STAR Market.
To date, Changde Medical has obtained 7 medical device registration certificates. Three products have completed pre-market clinical trial enrollment and entered the registration approval submission stage, while multiple products have initiated CE registration applications. Moreover, the company's self-developed EF-Lumber® Peripheral Drug-Eluting Stent is currently in the clinical enrollment phase and is expected to receive approval from the National Medical Products Administration (NMPA) in March 2025, entering the special review process for innovative medical devices ("Green Channel"). Since the first product, the EF-Rhine® Peripheral Vascular Constrained Balloon Dilation Catheter, was approved for marketing in December 2023, the company’s commercial promotion has rapidly expanded.
China's "Artificial Heart" Leading Enterprise Raises Over $100 Million in Financing
Recently, Shenzhen Core Medical Technology Co., Ltd. ("Core Medical"), an innovative medical device company, announced the completion of an oversubscribed $100 million+ Series D financing round. The funding will accelerate innovative product development, advance the company’s international strategic layout, enhance global competitiveness, and leverage China's innovative transformative power to continuously lead the global "artificial heart" industry.
This round of financing was jointly led by Loyal Valley Capital, the Social Security Fund Zhongguancun Independent Innovation Special Fund (managed by Legend Capital), Prosperity7 Ventures (P7) under Aramco Ventures, Cornerstone Capital, and well-known industry investors, with Delian Capital and Linknew Capital participating as followers.
Core Medical: Corheart 6, the World's Smallest and Lightest Fully Magnetically Levitated Left Ventricular Assist System, Tops Both Market Share and Cumulative Implant Volume
The implantation of artificial hearts and related research represent one of the most significant technological development directions in the field of cardiovascular surgery in recent years, offering guidance and expansion value at the academic level. According to data disclosed by the National Center for Cardiovascular Diseases and Fuwai Hospital, following the approval and market launch of Coreheart® 6, developed by CH Biomedical, in June 2023, the number of LVAD implants in China has doubled in the past two years. From 2017 to 2024, a total of 1,446 LVAD implant surgeries were completed across 187 hospitals in China. In terms of end-user implant volume, Coreheart® 6 held a 46% market share in China in 2024, ranking first in the industry. As of the end of 2024, its cumulative implant volume also ranked first in the industry. To date, the cumulative clinical application of Coreheart® 6 has exceeded 700 cases.
Core Medical expands the technological boundaries in the field of artificial hearts based on "time-sharing and zoning axial full magnetic suspension control technology," continuously leading the miniaturization of artificial hearts. It has developed a new generation of BiVAD product, DuoCor, as an integrated full magnetic suspension biventricular assist system. Featuring a single controller combined with an innovative control algorithm design, it achieves coordinated operation of the left and right pumps through one controller. With only one percutaneous cable extending outside the body, it significantly reduces the risk of infection. The two blood pumps work as a coordinated system, effectively simulating the heart's natural function and reducing the complexity and risks potentially caused by multiple independent devices within the patient’s body.
In addition, DuoCor's blood pump and internal components adopt a fully magnetically levitated lightweight design, which is small in size and light in weight. According to the needs of the patient's condition, flexible configurations such as left pump implantation, right pump implantation, and dual pump implantation can be achieved, greatly expanding the range of clinical indications.
DuoCor's external components are also more streamlined and lightweight, with longer battery life: a set of external components reduces the weight of external devices by more than 3-6 times compared to existing solutions, making it more portable overall; the system has lower overall power consumption, and with dual-battery support, even when both pumps are running simultaneously, frequent charging is unnecessary. Compared to existing solutions, the overall battery life is improved by over one-fold, comprehensively enhancing patients' quality of life.
From "Best-in-Class" to "First-in-Class," the core medical R&D integrated full magnetic levitation biventricular assist system DuoCor® has been applied in over 10 clinical cases. The product represents the most advanced international level, helping to address long-term treatment challenges in the field of right heart and biventricular failure globally, filling the "unexplored territory" in the global industry.
Over 100 Million Yuan! Shanghai Heyuan Medical Completes New Round of Financing
Recently, United InnoMed (Shanghai) Co., Ltd. (United InnoMed, abbreviated as "United Medical") announced new financing developments, successfully completing a new round of financing exceeding 100 million yuan. This round of financing was jointly led by Longpan Investment and Daotong Investment, with participation from Yinglian Health Fund and Tianrui Fengnian, and continued support from existing shareholder Lilly Asia Ventures. Dingshi Capital served as the exclusive financial advisor. The funds raised will mainly be used for the research and development and registration clinical trials of several core products under development by the company, providing more valuable solutions for heart failure patients.
Heyuan Medical was founded in 2020, with its headquarters located in Shanghai. It has been deeply engaged in the development of innovative Class III active implantable products and is committed to creating a cost-effective "closed-loop" heart failure management solution for heart failure patients worldwide. Heyuan Medical has demonstrated unique capabilities in the heart failure management sector, gradually establishing itself as an important player in the industry.Products and Technology: Heyuan Medical’s pipeline covers the management of both acute and chronic heart failure patients, forming a relatively comprehensive product portfolio. For chronic heart failure patients, it has launched long-term implantable products that integrate "treatment + diagnosis," achieving full integration throughout disease management. For hospitalized patients with acute heart failure, the company is developing short-term Electrical Circulatory Support devices, meeting treatment needs at different stages of the disease. All these products are independently developed and globally pioneering, showcasing strong technological innovation. The company has filed over a hundred domestic and international invention patents.
Nowadays, dozens of animal experiments have been completed, and clinical trials registered in China have also been initiated, bringing new hope for heart failure treatment. Heart failure, as the severe stage of cardiovascular diseases, has a high incidence rate and a large patient population. The current clinical diagnosis and treatment methods are limited, indicating a huge market demand. With its unique innovation and high technical barriers, complete layout, Heflow Medical's products are expected to effectively fill the market gap and meet the urgent needs in the field of heart failure management, demonstrating good market potential. Since its establishment, Heflow Medical has made smooth progress in financing. Before this round of financing that exceeded 100 million yuan, it had received multiple rounds of support from investors such as Lilly Asia Ventures, which continued to back Heflow Medical in several rounds, showing the investors' high recognition of the company’s R&D strength, product pipeline, and market prospects in the heart failure field. The funds raised in each round of financing were precisely invested in key areas such as product development and clinical trials, strongly promoting technological breakthroughs and product iteration upgrades, gradually perfecting the heart failure management product system.
Kossel Medical Completes Nearly 100 Million Yuan B+ Round Financing, Accelerating Platform Layout in the Full Field of Vascular Interventional Devices
Recently, Corseal Medical Technology (Suzhou) Co., Ltd. (hereinafter referred to as "Corseal Medical") announced the completion of a nearly 100-million-yuan B+ round of financing. This round of financing was led by the well-known Chinese investment institution Tie Tou Ju Shi, with continued additional investment from SND Finance Control and participation from Yuan Yong Investment. The funds will be used for core product research and development, global market promotion, and production capacity expansion. This round of financing demonstrates the investors' full recognition of Corseal Medical’s rapid and high-quality development and future potential, and also lays a solid foundation for Corseal Medical to consolidate its platform-based layout.
Kosel Medical, founded in 2013, has become a platform enterprise in the field of vascular interventional devices, forming a "one core, three wings" business layout: the parent company builds a "one-stop" treatment system for peripheral interventions (covering venous/arterial), subsidiary Haiyu Xincheng focuses on the cardiac electrophysiology field (providing comprehensive solutions for tachyarrhythmia treatment), subsidiary Mixin Medical concentrates on the research and development of coronary intervention products and overseas technology transfer, and subsidiary Haiwang Medical is committed to breaking through the "bottleneck" technology of medical core raw materials.
Kossel Medical actively implements the "Local Base, Global Reach" overseas strategy. In 2021, it acquired Irish company Micell, obtaining its global clinical data from thousands of cases and special coating technology, marking a solid first step in globalization. The company has completed product registration in over 20 countries abroad and plans to establish more overseas subsidiaries and offices. Global sales will officially commence in 2024, with scaled overseas expansion expected by 2026.
The company has invested over 300 million yuan in R&D, building a rich technical platform. It has a team of nearly a hundred people in R&D, process, and registration, owns hundreds of domestic and international invention patents (including nearly a hundred PCT patents), and holds more than 40 Class III medical device registration certificates in China and abroad (nearly 20 of which are international). Two innovative products have been successfully commercialized, achieving a leap from domestically produced alternatives to independent innovation. Keseal Medical has complete market, academic, and sales teams, with nearly 2,000 cooperative hospitals in China, and has become a recognized brand in the industry.
YaoSu Technology Receives Tens of Millions of Strategic Investment from Crystal Tech, Jointly Building a New Paradigm of "AI + Organ-on-a-Chip"
Xellar Co., Ltd. was founded in Boston, USA, at the end of 2021. It is the world’s first "3D-Wet-AI" biotech startup to leverage organ-on-a-chip technology combined with high-content three-dimensional (3D) cell imaging, computer vision (CV), and artificial intelligence (AI) for drug discovery and precision medicine research. The founding team of Xellar comprises members mostly from well-known multinational biopharmaceutical companies and top academic institutions such as Harvard University and MIT, bringing extensive experience in pharmaceutical product development and cutting-edge bio- and AI technology R&D. Xellar is currently the only organ-on-a-chip company globally working with the FDA and multinational pharmaceutical alliances to co-develop and establish next-generation preclinical drug efficacy testing standards based on organ-on-a-chip technology. Xellar has also initiated strategic and research collaborations with multiple biopharmaceutical companies and academic institutions.
Keyue Medical was founded in 2021, focusing on precise monitoring and treatment solutions for depression, anxiety, insomnia, and cognitive disorders. Keyue Medical is committed to the research, development, and manufacturing of non-invasive neuromodulation therapy devices and portable monitoring equipment in the central nervous system field. The company concentrates on precise monitoring and treatment solutions for depression, anxiety, insomnia, and cognitive disorders, with a product system covering physiological monitoring, auxiliary diagnosis, therapeutic intervention, and efficacy evaluation. Holding core patented technologies in the field of non-invasive neuromodulation, the company has applied for more than 70 related patents and has been granted 11 invention patents. It has participated in one key R&D project of the National Ministry of Science and Technology and one key R&D plan of the Shaanxi Provincial Department of Science and Technology. The company continues to focus on the prevention and treatment of psychiatric and neurological diseases, jointly establishing R&D centers and technology transfer bases with multiple universities, forming a technology transfer system that includes scientific research innovation, technological breakthroughs, and commercial validation, laying a solid foundation for product innovation.
Smart Medicine received Series A financing from Shunwang Technology on April 24.
Smart Medicine was established in June 2014 as one of the first operators of an appointment-based medical treatment platform. It is committed to becoming a new digital health economy operator driven by public internet hospitals, fully empowering high-quality development in healthcare and the equal distribution of quality medical resources. It promotes a patient-centered, whole-process proactive health management model across various scenarios, enhances residents' health literacy, and builds a digital medical and health economy industry chain.
Jinbaihui Biotech Obtains B+ Round Financing from Zhongshan Xibay Investment Co., Ltd. on April 25
Jinbaihui Biotech, founded in 2013, is headquartered in Shenzhen, China. Focused on cutting-edge in vitro diagnostic technologies and advanced molecular biology research related to cancer, the company consistently adheres to independent innovation and the transformation of scientific achievements. It possesses a complete industrial chain encompassing the research and development, production, and sales of diagnostic reagents and instruments, as well as third-party medical laboratory services. Jinbaihui Biotech provides comprehensive solutions in technology, reagents, instruments, and services for directions such as cancer diagnosis, point-of-care testing, and AI-based intelligent cancer staging.
Life Science Tools
Investment Dynamics in China
Aladdin announced that the company plans to invest in Shanghai Yamei Biomedical Technology Co., Ltd. (referred to as "Yamei Bio") through capital increase and purchase of existing shares, subscribing for a certain amount of new registered capital and existing shares of Yamei Bio.
The Company Will Invest RMB 41.17 Million to Hold 25% Stake in Yamei BiotechThe total investment amount of the Company in this investment is RMB 41.17 million. After the completion of this investment, the Company will hold 25% of the equity in Yamei Biotech. Established in 2019, Yamei Biotech is an enterprise specializing in the research, development, and production of scientific research tools in the life sciences field. Its product portfolio includes antibodies, ELISA kits, molecular enzymes, protein reagents, and cell biology products, among others. Particularly in the area of Western blotting, it provides comprehensive solutions, with products covering the entire line of reagents for protein extraction, protein quantification, electrophoresis and membrane transfer, antibodies, chemiluminescence, as well as electrophoresis equipment. This investment will support Yamei Biotech's research and production in the field of scientific research tools, further enhancing its R&D capabilities and market competitiveness.
This funding not only provides strong financial support for LaMont Bio's R&D progress but also highlights the potential and value of its innovative technology in the field of cancer immunotherapy. Previously, LaMont Bio had received capital favor multiple times, completing a nearly 100-million-yuan angel round of financing in January 2022, with a cumulative financing amount that is quite substantial.
Antibodies and Protein Drugs
Shunjing Pharmaceuticals Successfully Completes 300 Million RMB Strategic Financing, May Lead New Trends in Antibody Drugs in the Future
Shun Jing Pharmaceutical is a biopharmaceutical service provider whose core business focuses on the research and development of original antibody drugs, primarily involving innovative therapeutic drugs for indications such as cardiovascular and cerebrovascular diseases, cancer, and neurodegenerative diseases.
Chengdu Fanuosi Biopharmaceutical Technology Co., Ltd. Focuses on Innovative Drug Research, Completed Tens of Millions of Yuan in Series A Financing on April 29
Led by Zhejiang Hisun Pharmaceutical Co., Ltd., with Chengdu Renzhu Investment Co., Ltd. and others following suit. The funds raised this time will mainly be used to advance clinical and preclinical research on pharmaceutical pipelines for liver diseases and tumors, which is expected to accelerate the development of related innovative drugs and bring good news to patients.
Tianchen Biotech Received B+ Round Financing from Sanyi Capital and Tongyue Investment on April 24
Tianchen Biotech was established in 2020, focusing on the research and development of innovative drugs for autoimmune diseases, with an emphasis on allergy and complement fields.Tianchen Bio will complete the U.S. IND applications for LP-003 and LP-005 in the near future and initiate overseas bridging clinical studies. This marks the first major milestone in Tianchen Bio's international expansion, laying a solid foundation for the company’s strategic goal of achieving global development.
Hefei Keshengjingtai Biotechnology Co., Ltd. Announces Completion of Latest Round of Financing on April 28
Although the specific financing amount has not been disclosed yet, the participation of investment institutions such as Anhui High-Tech Investment and Binhu Construction Investment demonstrates market confidence in its development prospects. The company's deep cultivation in the biopharmaceutical R&D field may bring new solutions for the treatment of related diseases.
About BGI Co-Win
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)